Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12722994 | 0.97 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9APDGFRBKDR | |
| SCHEMBL12722995 | 0.97 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9APDGFRBKDR | |
| SCHEMBL20384882 | 0.94 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1RAB9APDGFRBKDR | |
| SCHEMBL16543263 | 0.94 | ASIC3 (0.41) | SMN1; SMN2NPC1RAB9APDGFRBKDR | |
| SCHEMBL14803495 | 0.93 | NPC1 (0.37) | SMN1; SMN2NPC1RAB9APDGFRBKDR | |
| SCHEMBL16543264 | 0.92 | ASIC3 (0.40) | SMN1; SMN2NPC1RAB9APDGFRBKDR | |
| SCHEMBL12722999 | 0.89 | KIF11 (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL21351492 | 0.89 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9APDGFRBKDR | |
| SCHEMBL21351295 | 0.89 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9APDGFRBKDR | |
| SCHEMBL14803483 | 0.87 | NPC1 (0.39) | SMN1; SMN2NPC1RAB9APDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252624-B1 | ELECTROLUMINESCENT METAL COMPLEXES WITH DIBENZO[F,H]QUINOXALINES | UDC IRELAND LTD (IE) | 2018-07-18 | — | — | EP | disclosed |
| US-8471248-B2 | Electroluminiscent metal complexes with dibenzo[f,h] quinoxalines | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8471248-B2 | Electroluminiscent metal complexes with dibenzo[f,h] quinoxalines | BASF SE (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20110089407-A1 | ELECTROLUMINISCENT METAL COMPLEXES WITH DIBENZO[F,H] QUINOXALINES | BASF SE (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110089407-A1 | ELECTROLUMINISCENT METAL COMPLEXES WITH DIBENZO[F,H] QUINOXALINES | BASF SE (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2009100991-A1 | ELECTROLUMINESCENT METAL COMPLEXES WITH DIBENZO[F,H]QUINOXALINES | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110089407-A1 | ELECTROLUMINISCENT METAL COMPLEXES WITH DIBENZO[F,H] QUINOXALINES | NDUFS2, NDUFS5, NDUFS3 | SMN1; SMN2 4424/4885NPC1 4653/4885RAB9A 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.